Recent randomized trials [1, 2] have demonstrated the renal and cardiovascular benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in chronic kidney disease (CKD) patients, irrespective of diabetes status. Here, SLC5A2 is linked to chronic kidney disease.